Mechanistic studies of high-density lipoproteins

American Journal of Cardiology

Volumn 82, Issue 12 A, 1998, Pages 42U-48U

  Kashyap, Moti L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ESTROGEN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HEART PROTECTION; HUMAN; LIFESTYLE; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032542239     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00813-3     Document Type: Conference Paper

References (26)

1. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976;294: 293-298.
2. Miller GJ, Miller NE. Plasma high-density lipoprotein concentrations in ischemic heart disease. Lancet 1975;:16-19.
3. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspective based on the Framingham Heart Study. Ann Intern Med 1979;90:85-91.
4. McNerney CA, Kashyap ML, Barnhart RL, Jackson RL. Comparison of gradient gel electrophoresis and zonal ultracentrifugation for quantitation of high-density lipoproteins. J Lipid Res 1985;26:1363-1367.
5. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res 1984;25:1017-1058.
6. Shultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365:762-764.
7. Fielding CJ, Fielding PE. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin: cholesterol acyltransferase. Proc Natl Acad Sci USA 1981;78:3911-3914.
8. Saku K, Reddy GS, Hynd BA, Kashyap ML. Renal handling of high-density lipoproteins by isolated perfused kidneys. Metabolism 1984;33:432-438.
9. Acton S, Rigotti A, Landschutz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor. Science 1996;271:518-520.
10. Steinberg D. A docking receptor for HDL cholesterol esters. Science 1996; 271:460-461.
11. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man. Thromb Res 1985; 39:1-8.
12. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044:275-283.
13. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high-density lipoproteins during alimentary lipemia in man. J Clin Invest 1973;52:32-38.
14. Ginsburg GS, Safran C, Pasternak C. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with "desirable" total cholesterol levels. Am J Cardiol 1991;68:187-192.
15. Bloomfield-Rubins H, Robins SJ, Iwane MK, Boden WE, Elam MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT, for the Department of Veterans Affairs HIT Study Group. Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol intervention trial (HIT) for secondary prevention of coronary artery disease in men with low HDL-C and desirable LDL cholesterol. Am J Cardiol 1993;71:45-52.
16. 2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-2028.
17. Blum CB, Levy RI, Eisenberg S, Hall M III, Goebel RH, Berman M. High-density lipoprotein metabolism in man. J Clin Invest 1977;60:795-807.
18. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of nicotinic acid therapy on plasma high-density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979;63: 858-867.
19. 2). Arterioscler Thromb Vasc Biol 1996;16:1052-1062.
20. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994;269:31012-31018.
21. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1995;75:1702-1712.
22. Jin FY, Kamanna VS, Kashyap ML. Estradiol stimulates apolipoprotein A-I but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells. Arterioscler Thromb Vasc Biol 1998;18:999-1006.
23. Amarasuriya RN, Gupta AK, Civen M, Maeda T, Kashyap ML. Ethanol stimulates apolipoprotein A-I secretion in human hepatocytes: implications for atherosclerosis protection. Metabolism 1992;41:827-832.
24. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Koren E, Fruchart JC. Apolipoprotein A-I-containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35-40.
25. Manninen V, Elo MO, Frick MH. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-651.
26. Gotto AM. Lipid lowering, regression and coronary events. Circulation 1995;92:646-656.